$CSCIF News

COSCIENS ANNOUNCES NEW CORPORATE PRESENTATION AND PROVIDES UPDATE ON CONVERTIBLE DEBENTURE OFFERING

COSCIENS COMPLETES SECOND TRANCHE OF CONVERTIBLE DEBENTURE OFFERING

COSCIENS Biopharma Acquires Pharma Tech Business Nualtis For $15 Million Cash

COSCIENS ACQUIRES NUALTIS CORP.

COSCIENS Biopharma Inc. Reports Q2 2026 Results

COSCIENS Biopharma Inc. Completes Share Capital Amendment

COSCIENS Biopharma Inc. Announces Results of Shareholder Meeting and Appointment of Full-Time CEO

COSCIENS Biopharma Inc. Reports Q1 2026 Results

Cosciens Biopharma Q1 EPS $2.90 Up From $(1.16) YoY, Sales $1.888M Up From $1.387M YoY

COSCIENS Biopharma Inc. Provides Update on its Plan to Suspend U.S. Public Company Reporting Obligations

Cosciens Biopharma Q4 EPS $(0.69) Up From $(2.15) YoY, Sales $1.766M Down From $3.300M YoY

COSCIENS Biopharma to Stop Funding Aeterna Zentaris GmbH and Zentaris IVF GmbH

COSCIENS Provides Strategic Update

COSCIENS Announces Exclusive Distribution Agreement with Wuzhou Drug International for Macrilen® in Hainan-Guangdong-Hong Kong-Macao Greater Bay Area and Singapore

COSCIENS Biopharma Signs 10-Year Exclusive Distribution Deal With Wuzhou For Macrilen In Hong Kong, Macao, Singapore, Guangdong, And Hainan, Including Minimum Initial Order Of €800,000

COSCIENS Biopharma Inc. Announces Leadership Change

COSCIENS Biopharma: Q3 Earnings Snapshot

COSCIENS Biopharma Inc. Reports Third Quarter 2025 Financial Results and Provides Strategic Initiatives Update

COSCIENS Biopharma Announces Results of Virtual 2025 Meeting of Shareholders

COSCIENS Biopharma Inc. Reconstitutes Board for Benefit of Shareholders